Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A26-38
Last updated

Report documents

  1. Extract of dossier assessment

    Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 305 kB, DE, not accessible
    Download file : Extract of dossier assessment (PDF document, 305 kB, DE, not accessible)

  2. Dossier assessment

    Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 1 MB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A26-38
    Download file : Dossier assessment (PDF document, 1 MB, DE, not accessible)

Drug assessment at a glance

  1. Drug assessment at a glance

    Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 209 kB, EN, not accessible
    Download file : Drug assessment at a glance (PDF document, 209 kB, EN, not accessible)

Dossier assessment

Indication:

Adults with relapsed or refractory multiple myeloma

Result of dossier assessment:
  • Patients who have received one to three prior therapies: added benefit not proven
  • Patients who have received at least four prior therapies: added benefit not proven

Additional information

Federal Joint Committee (GBA)

01-10-2026 A G-BA decision was published.
GBA documents on this decision

Project details

Project no.
A26-38
Commission
Commission awarded on 01.04.2026 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A26-38

Connected Projects

  1. Dossier assessment

    Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G20-22
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Belantamab mafodotin (multiple myeloma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (expiry of the decision)

    Project no.
    G23-05
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Belantamab mafodotin (multiple myeloma; combination with pomalidomide and dexamethasone) – Benefit assessment according to §35a Social Code Book V35a Social Code Book V

    Project no.
    A26-39
    Last updated

    Status: Commission completed

  4. Addendum

    Belantamab mafodotin (multiple myeloma; combination with bortezomib and dexamethasone) – Addendum to Project A26-38

    Project no.
    A26-102
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page